普罗布考与氧化型低密度脂蛋白相关研究进展

摘要

近年来,大量的药理及临床试验发现调脂药普罗布考可稳定和消退动脉粥样硬化斑块,改善血管内皮功能,具有较好的抗动脉粥样硬化作用.氧化型低密度脂蛋白是引起动脉粥样硬化的主要危险因素.普罗布考可作用于氧化型低密度脂蛋白抑制其进一步氧化修饰,发挥抗氧化作用;也可通过抑制氧化型低密度脂蛋白诱导单核巨噬细胞产生的各种重要炎性细胞因子的表达而发挥抗炎作用;还可改善血管平滑肌的增殖,维持凝血、纤溶系统平衡等.普罗布考可通过多个靶点作用于氧化型低密度脂蛋白发挥抗氧化、抗炎、保护血管内皮、抗动脉粥样硬化作用.%In recent years a number of pharmacological and clinical trials found that lipid drug probucol can stabilize and dissipate atherosclerotic plaque,improving vascular endothelia function,and has better anti-atherosclerosis effect. Oxidized low-density lipoprotein is the major risk factor causing atherosclerosis. Probucol can react on the oxidized low-density lipoprotein and inhibit its further oxidative modification, thus playing an antioxidant role; or play an anti-inflammatory role by inhibiting the expression of various important inflammatory factors produced by monocyte-macrophage cells induced by the oxidized low-density lipoprotein ; it can also improve the proliferation of vascular smooth muscle cells, maintain the coagulation and fibrinolytic system in balance. Probucol can play the role of anti-oxidant,anti-inflammatory,protecting the vascular endo-thelium, anti-atherosclerosis through multiple targets of oxidized low-density lipoprotein.